18_CD Operating_NN and_CC financial_JJ review_NN How_WRB we_PRP manage_VBP our_PRP$ business_NN :_: finance_NN and_CC risk_NN We_PRP have_VBP put_VBN in_IN place_NN robust_JJ systems_NNS to_TO manage_VB our_PRP$ financial_JJ practices_NNS and_CC areas_NNS that_WDT put_VBP Acambis_NNP business_NN at_IN risk_NN ._.
Over_IN the_DT last_JJ few_JJ years_NNS ,_, we_PRP have_VBP particularly_RB focused_VBN on_IN improving_VBG our_PRP$ handling_NN of_IN risks_NNS by_IN embedding_VBG a_DT risk_NN management_NN framework_NN into_IN our_PRP$ operations_NNS ._.
Financial_NNP systems_NNS The_DT following_JJ section_NN sets_VBZ out_RP some_DT of_IN exchange_NN rate_NN exposures_NNS ,_, given_VBN our_PRP$ smallpox_NN vaccine_NN contract_NN ._.
Owing_VBG to_TO the_DT main_JJ financial_JJ parameters_NNS through_IN reporting_VBG currency_NN is_VBZ sterling_NN ._.
the_DT timing_NN of_IN certain_JJ costs_NNS under_IN that_DT which_WDT we_PRP manage_VBP our_PRP$ business_NN ._.
We_PRP manage_VBP our_PRP$ cash_NN in_IN money_NN market_NN contract_NN ,_, some_DT funds_NNS have_VBP been_VBN received_VBN funds_NNS with_IN the_DT aid_NN of_IN professional_JJ money_NN in_IN advance_NN of_IN costs_NNS having_VBG been_VBN incurred_VBN CAPITAL_NNP STRUCTURE_NN market_NN managers_NNS ._.
The_DT Board_NNP regularly_RB and_CC ,_, as_IN a_DT result_NN ,_, this_DT will_MD give_VB rise_VB to_TO a_DT At_IN the_DT end_NN of_IN 2003_CD ,_, Acambis_NNP had_VBD reviews_VBZ the_DT performance_NN of_IN those_DT funds_NNS large_JJ negative_JJ cash_NN movement_NN in_IN 2004_CD ._.
approximately_RB 125m_JJ invested_VBN in_IN cash_NN to_TO ensure_VB they_PRP achieve_VB competitive_JJ rates_NNS and_CC short-term_JJ investments_NNS ._.
Our_PRP$ treasury_NN policy_NN ensures_VBZ CURRENT_NNP LIQUIDITY_NN that_WDT through_IN the_DT course_NN of_IN 2004_CD this_DT that_IN our_PRP$ capital_NN is_VBZ not_RB at_IN risk_NN ._.
During_IN As_IN referred_VBN to_TO within_IN Capital_NN structure_NN ,_, will_MD reduce_VB to_TO nearer_IN 100m_CD as_IN a_DT large_JJ 2003_CD ,_, we_PRP hedged_VBD certain_JJ foreign_JJ we_PRP currently_RB have_VBP a_DT lease-financing_JJ working_NN capital_NN movement_NN unwinds_VBZ ._.
exchange_NN exposures_NNS but_CC did_VBD not_RB have_VB facility_NN in_IN relation_NN to_TO the_DT reactivation_NN Given_VBN our_PRP$ healthy_JJ cash_NN balance_NN we_PRP have_VBP any_DT instruments_NNS outstanding_JJ at_IN the_DT of_IN our_PRP$ manufacturing_NN facility_NN ._.
At_IN the_DT not_RB had_VBD to_TO increase_VB our_PRP$ debt_NN profile_NN end_NN of_IN the_DT year_NN ._.
We_PRP manage_VBP this_DT area_NN end_NN of_IN 2003_CD ,_, $_$ 22.5_CD m_NN c._NN 12.6_CD m_NN of_IN in_IN the_DT last_JJ couple_NN of_IN years_NNS ._.
on_IN an_DT ongoing_JJ basis_NN to_TO ensure_VB that_IN ,_, a_DT potential_JJ $_$ 40m_CD had_VBD been_VBN drawn_VBN At_IN 31_CD December_NNP 2003_CD ,_, we_PRP had_VBD $_$ 29.5_CD m_NN where_WRB possible_JJ ,_, potential_JJ areas_NNS of_IN risk_NN down_IN from_IN the_DT facility_NN ._.
We_PRP do_VBP not_RB 16.5_CD m_NN of_IN US_NNP dollar-denominated_JJ debt_NN are_VBP appropriately_RB mitigated_VBN ._.
currently_RB envisage_NN utilising_VBG the_DT on_IN our_PRP$ balance_NN sheet_NN ,_, comprising_VBG Of_IN the_DT $_$ 29.5_CD m_NN 16.5_CD m_NN US_NNP dollarundrawn_JJ amount_NN ._.
a_DT lease-financing_JJ facility_NN for_IN the_DT denominated_VBN debt_NN as_IN referred_VBN to_TO within_IN reactivation_NN of_IN our_PRP$ manufacturing_NN Capital_NN Structure_NNP ,_, the_DT interest_NN rate_NN INTERNAL_JJ SOURCES_NNS OF_IN LIQUIDITY_NN plant_NN and_CC an_DT overdraft_NN facility_NN for_IN the_DT payable_JJ on_IN the_DT $_$ 22.5_CD m_NN finance_NN lease_NN is_VBZ The_DT Group_NNP has_VBZ a_DT number_NN of_IN interARILVAX_NNP program_NN ._.
Under_IN the_DT fixed_VBN at_IN 6.25_CD %_NN per_IN annum_NN for_IN the_DT life_NN company_NN agreements_NNS between_IN its_PRP$ current_JJ terms_NNS of_IN these_DT arrangements_NNS ,_, of_IN the_DT lease_NN :_: and_CC the_DT $_$ 7m_CD ARILVAX_NNP companies_NNS that_WDT have_VBP historically_RB both_DT these_DT debts_NNS will_MD be_VB repaid_VBN within_IN overdraft_NN facility_NN is_VBZ charged_VBN at_IN 0.35_CD %_NN been_VBN put_VBN in_IN place_NN to_TO secure_VB the_DT the_DT next_JJ three_CD years_NNS ._.
per_IN annum_NN above_IN the_DT bank_NN base_NN rate_NN long-term_JJ funding_NN requirements_NNS We_PRP believe_VBP that_IN our_PRP$ cash_NN will_MD be_VB for_IN US_NNP dollars_NNS ._.
of_IN each_DT of_IN those_DT companies_NNS ._.
sufficient_JJ for_IN the_DT operational_JJ needs_NNS of_IN our_PRP$ business_NN for_IN the_DT medium-term_JJ ._.
CASH_NN FLOWS_NNS GOING_VBG CONCERN_NNP STATEMENT_NNP During_IN 2003_CD ,_, the_DT net_JJ cash_NN and_CC liquid_JJ The_DT Directors_NNS have_VBP a_DT reasonable_JJ TREASURY_NN POLICY_NNP resources_NNS inflow_NN for_IN the_DT Group_NNP was_VBD expectation_NN that_IN the_DT Company_NN and_CC The_DT Group_NNP holds_VBZ its_PRP$ cash_NN in_IN a_DT mix_NN of_IN 113.4_CD m_NN ,_, with_IN 119.1_CD m_NN derived_VBN from_IN the_DT Group_NNP have_VBP adequate_JJ resources_NNS sterling_NN ,_, US_NNP dollars_NNS and_CC euros_NNS ._.
Cash_NN is_VBZ operating_VBG activities_NNS and_CC a_DT net_JJ cash_NN and_CC to_TO continue_VB their_PRP$ operations_NNS for_IN the_DT invested_VBN in_IN this_DT range_NN of_IN currencies_NNS such_JJ liquid_JJ resources_NNS outflow_NN of_IN 5.7_CD m_NN from_IN foreseeable_JJ future_NN ._.
As_IN a_DT result_NN ,_, the_DT that_WDT working_VBG capital_NN requirements_NNS for_IN investment_NN and_CC financing_NN activities_NNS ._.
Directors_NNS have_VBP adopted_VBN the_DT going_VBG the_DT components_NNS of_IN the_DT Group_NNP can_MD be_VB By_IN the_DT end_NN of_IN 2003_CD ,_, we_PRP had_VBD received_VBN concern_NN basis_NN in_IN preparing_VBG the_DT met_VBN ._.
Where_WRB appropriate_JJ ,_, it_PRP is_VBZ our_PRP$ policy_NN the_DT vast_JJ majority_NN of_IN cash_NN due_JJ from_IN our_PRP$ financial_JJ statements_NNS ._.
to_TO invest_VB surplus_NN funds_NNS in_IN sterling_NN ,_, largest_JJS customer_NN ,_, the_DT US_NNP Centers_NNPS for_IN which_WDT currently_RB attracts_VBZ a_DT higher_JJR Disease_NNP Control_NNP and_CC Prevention_NNP CDC_NNP ,_, interest_NN rate_NN and_CC mitigates_NNS certain_JJ in_IN respect_NN of_IN our_PRP$ $_$ 428m_CD c._NN 240m_JJ 19_CD Risk_NN management_NN Over_IN the_DT last_JJ few_JJ years_NNS we_PRP have_VBP As_IN our_PRP$ business_NN has_VBZ matured_VBN over_IN Section_NN 404_CD Attestation_NNP Management_NNP given_VBN priority_NN to_TO embedding_VBG a_DT risk_NN the_DT last_JJ few_JJ years_NNS from_IN a_DT loss-making_JJ Assessment_NNP of_IN Internal_NNP Control_NNP ,_, with_IN management_NN framework_NN into_IN the_DT R&D_NNP organization_NN to_TO a_DT fully_RB integrated_VBN Auditor_NNP Attestation_NNP of_IN the_DT Sarbanes_NNP operations_NNS of_IN our_PRP$ business_NN ._.
All_DT profitable_JJ biotechnology_NN company_NN ,_, Oxley_NNP Act_NNP of_IN 2002_CD in_IN the_DT US_NNP ._.
managers_NNS are_VBP encouraged_JJ proactively_RB this_DT has_VBZ brought_VBN with_IN it_PRP new_JJ risks_NNS for_IN We_PRP do_VBP not_RB currently_RB have_VBP a_DT formal_JJ to_TO manage_VB risk_NN within_IN their_PRP$ own_JJ the_DT business_NN to_TO manage_VB ._.
The_DT structure_NN internal_JJ audit_NN function_NN ._.
However_RB ,_, the_DT area_NN and_CC to_TO identify_VB potential_JJ areas_NNS of_IN we_PRP have_VBP developed_VBN to_TO manage_VB risk_NN Audit_NNP Committee_NNP regularly_RB reviews_VBZ exposure_NN ._.
The_DT Executive_NNP Directors_NNS are_VBP is_VBZ both_DT robust_JJ and_CC flexible_JJ ,_, enabling_VBG this_DT requirement_NN and_CC will_MD do_VB so_RB again_RB responsible_JJ for_IN reporting_VBG to_TO the_DT Board_NNP us_PRP to_TO add_VB in_IN new_JJ components_NNS as_IN our_PRP$ during_IN 2004_CD ._.
via_IN the_DT Audit_NNP Committee_NNP on_IN our_PRP$ risk_NN business_NN changes_NNS ._.
We_PRP also_RB engage_VBP a_DT number_NN of_IN external_JJ management_NN program_NN ._.
Early_RB in_IN 2004_CD ,_, we_PRP assigned_VBD a_DT parties_NNS to_TO ensure_VB we_PRP are_VBP covering_VBG all_DT We_PRP are_VBP conscious_JJ that_IN managing_VBG dedicated_JJ resource_NN to_TO assess_VB and_CC test_VB risk_NN areas_NNS ,_, from_IN consultants_NNS to_TO auditors_NNS ,_, risk_NN is_VBZ an_DT ongoing_JJ process_NN and_CC we_PRP our_PRP$ internal_JJ controls_NNS to_TO ensure_VB we_PRP from_IN legal_JJ advisers_NNS to_TO insurers_NNS ._.
continue_VB to_TO build_VB on_IN it_PRP each_DT year_NN ._.
comply_VB as_IN a_DT foreign_JJ registrant_NN with_IN This_DT is_VBZ a_DT summary_NN of_IN some_DT of_IN the_DT main_JJ risks_NNS to_TO which_WDT Acambis_NNP is_VBZ currently_RB exposed_VBN :_: having_VBG only_RB one_CD main_JJ revenue_NN stream_NN ,_, which_WDT is_VBZ generated_VBN by_IN sales_NNS of_IN our_PRP$ investigational_JJ smallpox_NN vaccine_NN to_TO governments_NNS :_: the_DT lack_NN of_IN a_DT substantial_JJ recurring_VBG revenue_NN stream_NN :_: the_DT ever-increasing_JJ requirements_NNS of_IN the_DT regulatory_JJ process_NN in_IN respect_NN of_IN our_PRP$ seven_CD products_NNS in_IN clinical_JJ development_NN :_: and_CC potential_JJ failure_NN of_IN a_DT product_NN in_IN clinical_JJ development_NN ._.
WE_NNP VIEW_NNP THE_DT RISKS_NNS TO_TO ACAMBIS_NNP IN_IN THE_DT FOLLOWING_VBG WAY_NN :_: Involving_VBG external_JJ parties_NNS in_IN the_DT Risks_NNS common_JJ to_TO all_DT businesses_NNS process_NN brings_VBZ impartiality_NN and_CC e._FW g._FW GOVERNMENT_NNP LEGISLATION_NNP objectivity_NN to_TO the_DT process_NN ,_, thereby_RB ultimately_RB serving_VBG to_TO manage_VB the_DT business_NN better_RBR for_IN all_DT stakeholders_NNS ._.
Risks_NNS common_JJ to_TO biotech_JJ businesses_NNS We_PRP provide_VBP further_JJ information_NN e._FW g._FW PRODUCT_NN FAILURE_NN on_IN this_DT risk_NN management_NN process_NN ,_, general_JJ risks_NNS to_TO which_WDT all_DT businesses_NNS are_VBP exposed_VBN and_CC a_DT summary_NN of_IN some_DT Risks_NNS common_JJ to_TO of_IN the_DT more_RBR specific_JJ risks_NNS to_TO which_WDT vaccine_NN companies_NNS Acambis_NNP is_VBZ exposed_VBN on_IN pages_NNS 28_CD to_TO 33_CD ._.
e._FW g._FW REGULATORY_NNP ISSUES_NNS Risks_NNS specific_JJ to_TO Acambis_NNP e._FW g._FW LOSS_NNPS OF_IN CERTAIN_NNP EMPLOYEES_NNPS 20_CD Operating_NN and_CC financial_JJ review_NN How_WRB we_PRP manage_VBP our_PRP$ business_NN :_: CSR_NNP We_PRP recognize_VBP that_IN there_EX is_VBZ an_DT increasing_VBG interest_NN in_IN the_DT Corporate_JJ Social_NNP Responsibility_NNP CSR_NNP activities_NNS of_IN companies_NNS such_JJ as_IN Acambis_NNP ._.
During_IN the_DT last_JJ year_NN ,_, we_PRP have_VBP been_VBN analyzing_VBG the_DT diverse_JJ information_NN requirements_NNS of_IN our_PRP$ various_JJ stakeholders_NNS in_IN order_NN to_TO identify_VB what_WP they_PRP most_RBS want_VBP to_TO know_VB about_IN how_WRB we_PRP run_VBP our_PRP$ business_NN ._.
From_IN this_DT analysis_NN ,_, we_PRP have_VBP identified_VBN five_CD key_JJ areas_NNS :_: employees_NNS ,_, health_NN and_CC safety_NN ,_, environmental_JJ impact_NN ,_, community_NN involvement_NN and_CC issues_NNS specific_JJ to_TO our_PRP$ industry_NN ._.
We_PRP are_VBP undertaking_VBG an_DT audit_NN of_IN our_PRP$ activities_NNS which_WDT ,_, in_IN addition_NN to_TO these_DT key_JJ areas_NNS ,_, is_VBZ looking_VBG at_IN relationships_NNS with_IN customers_NNS and_CC suppliers_NNS ._.
We_PRP plan_VBP to_TO publish_VB the_DT information_NN we_PRP compile_VBP on_IN these_DT activities_NNS on_IN our_PRP$ website_JJ www_NN ._.
Here_RB ,_, we_PRP are_VBP publishing_VBG an_DT overview_NN of_IN our_PRP$ activities_NNS in_IN these_DT key_JJ areas_NNS ._.
DEVELOPING_VBG VACCINES_NNS TO_TO SAVE_VB LIVES_NNP The_DT most_RBS important_JJ aspect_NN of_IN Acambis_NNP contribution_NN to_TO society_NN is_VBZ the_DT work_NN we_PRP do_VBP day_NN in_IN ,_, day_NN out_IN :_: developing_VBG new_JJ vaccines_NNS against_IN infectious_JJ diseases_NNS ._.
The_DT disease_NN areas_NNS we_PRP are_VBP targeting_VBG affect_VB the_DT lives_NNS of_IN tens_NNS of_IN millions_NNS of_IN people_NNS every_DT year_NN ._.
For_IN instance_NN ,_, there_EX are_VBP an_DT estimated_VBN 50_CD million_CD cases_NNS of_IN dengue_NN infection_NN every_DT year_NN ,_, of_IN which_WDT 500,000_CD develop_VB into_IN the_DT more_RBR severe_JJ dengue_NN hemorrhagic_JJ fever_NN ,_, which_WDT has_VBZ an_DT average_JJ 20_CD %_NN fatality_NN rate_NN ._.
There_EX is_VBZ no_DT licensed_JJ vaccine_NN against_IN dengue_NN ._.
Our_PRP$ investigational_JJ vaccine_NN is_VBZ undergoing_VBG clinical_JJ testing_NN ._.
Even_RB in_IN the_DT case_NN of_IN our_PRP$ smallpox_NN vaccine_NN ,_, where_WRB the_DT virus_NN is_VBZ no_RB longer_RB WORLDWIDE_NNP DISTRIBUTION_NNPS OF_IN DENGUE_NNP SOURCE_NNP :_: CDC_NNP circulating_VBG ,_, we_PRP are_VBP playing_VBG an_DT important_JJ part_NN in_IN worldwide_JJ preparations_NNS to_TO defend_VB AREAS_NNP INFESTED_NNP WITH_IN DENGUE-TRANSMITTING_NNP MOSQUITO_NNP against_IN a_DT potentially_RB catastrophic_JJ AREAS_NNP WITH_IN DENGUE-TRANSMITTING_NNP MOSQUITO_NNP AND_CC DENGUE_NNP EPIDEMIC_NNP ACTIVITY_NNP bioterrorist_NN event_NN ._.
21_CD OUR_NNP EMPLOYEES_NNS ENVIRONMENTAL_JJ MANAGEMENT_NN INDUSTRY_NN ISSUES_NNS Much_JJ of_IN our_PRP$ value_NN and_CC potential_NN for_IN The_DT biotechnology_NN industry_NN is_VBZ generally_RB In_IN our_PRP$ industry_NN ,_, there_EX are_VBP a_DT number_NN success_NN sits_VBZ with_IN our_PRP$ employees_NNS and_CC recognized_VBN as_IN having_VBG a_DT relatively_RB low_JJ of_IN ethical_JJ issues_NNS that_IN a_DT company_NN such_JJ the_DT intellectual_JJ capital_NN they_PRP represent_VBP impact_NN on_IN the_DT environment_NN in_IN terms_NNS of_IN as_IN Acambis_NNP needs_VBZ to_TO address_VB ._.
through_IN their_PRP$ experience_NN and_CC expertise_NN ._.
emissions_NNS and_CC use_NN of_IN materials_NNS ._.
A_DT waste_NN The_DT most_RBS high_JJ profile_NN of_IN these_DT is_VBZ We_PRP believe_VBP in_IN rewarding_VBG them_PRP production_NN survey_NN conducted_VBN at_IN one_CD of_IN the_DT use_NN of_IN animals_NNS to_TO test_NN products_NNS appropriately_RB for_IN the_DT contribution_NN they_PRP our_PRP$ sites_NNS a_DT few_JJ years_NNS ago_IN confirmed_VBD this_DT before_IN they_PRP advance_VBP to_TO clinical_JJ trials_NNS make_VBP to_TO our_PRP$ success_NN ,_, both_DT through_IN their_PRP$ view_NN ._.
We_PRP are_VBP continuing_VBG to_TO assess_VB our_PRP$ in_IN humans_NNS ._.
This_DT type_NN of_IN testing_NN is_VBZ remuneration_JJ and_CC through_IN an_DT annual_JJ activities_NNS in_IN this_DT area_NN and_CC to_TO identify_VB required_VBN by_IN law_NN in_IN our_PRP$ home_NN territories_NNS bonus_NN scheme_NN that_WDT is_VBZ linked_VBN to_TO personal_JJ and_CC act_NN upon_IN ways_NNS to_TO reduce_VB what_WP of_IN the_DT UK_NNP and_CC the_DT US_NNP and_CC is_VBZ undertaken_VBN and_CC company_NN performance_NN ._.
within_IN a_DT very_RB strict_JJ and_CC well_RB regulated_VBN We_PRP aim_VBP to_TO involve_VB our_PRP$ employees_NNS framework_NN ._.
We_PRP apply_VBP rigorous_JJ standards_NNS closely_RB in_IN the_DT Groups_NNS progress_NN through_IN COMMUNITY_NNP INVOLVEMENT_NNP to_TO any_DT such_JJ work_NN ,_, including_VBG oversight_NN share_NN ownership_NN ._.
All_DT employees_NNS are_VBP Our_PRP$ community_NN activities_NNS focus_VB on_IN two_CD by_IN internal_JJ and_CC external_JJ ethical_JJ review_NN awarded_VBN share_NN options_NNS when_WRB they_PRP join_VBP key_JJ areas_NNS :_: supporting_VBG employees_NNS efforts_NNS committees_NNS and_CC enforcement_NN of_IN the_DT Acambis_NNP and_CC at_IN other_JJ times_NNS during_IN their_PRP$ to_TO raise_VB funds_NNS for_IN charity_NN :_: and_CC involvement_NN three_CD Rs_NNS concept_NN refine_VB ,_, reduce_VB ,_, employment_NN ,_, and_CC they_PRP are_VBP also_RB given_VBN with_IN organizations_NNS or_CC events_NNS related_VBN replace_VB ._.
We_PRP have_VBP always_RB sought_VBN to_TO the_DT opportunity_NN to_TO participate_VB in_IN share_NN to_TO promotion_NN of_IN conduct_NN such_JJ work_NN in_IN countries_NNS such_JJ as_IN save_IN schemes_NNS ._.
the_DT UK_NNP and_CC the_DT US_NNP where_WRB the_DT highest_JJS Our_PRP$ decision_NN in_IN January_NNP 2004_CD to_TO We_PRP match_VBP the_DT amount_NN of_IN money_NN raised_VBD ethical_JJ standards_NNS are_VBP applied_VBN ._.
close_RB the_DT UK_NNP research_NN operations_NNS by_IN an_DT employee_NN or_CC group_NN of_IN employees_NNS A_DT major_JJ question_NN facing_VBG vaccine_NN following_VBG a_DT portfolio_NN and_CC operational_JJ for_IN their_PRP$ chosen_VBN charity_NN ._.
In_IN 2003_CD ,_, we_PRP developers_NNS and_CC drug_NN manufacturers_NNS review_NN was_VBD a_DT difficult_JJ one_CD to_TO take_VB ,_, introduced_VBD a_DT Payroll_NNP Giving_NNP Scheme_NNP in_IN the_DT today_NN is_VBZ how_WRB to_TO make_VB the_DT products_NNS particularly_RB in_IN making_VBG 40_CD employees_NNS UK_NNP to_TO enable_VB employees_NNS to_TO donate_VB to_TO the_DT available_JJ to_TO the_DT areas_NNS of_IN the_DT world_NN redundant_NN ._.
The_DT decision_NN was_VBD driven_VBN charities_NNS of_IN their_PRP$ choice_NN through_IN payroll_NN ,_, where_WRB they_PRP are_VBP most_RBS needed_VBN ,_, even_RB by_IN specific_JJ operational_JJ business_NN needs_NNS ._.
which_WDT has_VBZ tax_NN benefits_NNS for_IN charities_NNS ._.
if_IN those_DT people_NNS are_VBP unable_JJ to_TO afford_VB We_PRP aimed_VBN to_TO be_VB as_IN fair_JJ as_IN possible_JJ with_IN Occasionally_RB ,_, we_PRP make_VBP donations_NNS to_TO to_TO buy_VB the_DT product_NN themselves_PRP ._.
the_DT employees_NNS affected_VBN and_CC ran_VBD a_DT full_JJ charities_NNS that_WDT support_VBP the_DT communities_NNS We_PRP want_VBP to_TO ensure_VB our_PRP$ vaccines_NNS are_VBP 30-day_JJ consultation_NN to_TO ensure_VB their_PRP$ in_IN which_WDT we_PRP operate_VBP ._.
Charitable_JJ made_VBN as_IN widely_RB available_JJ as_IN possible_JJ ._.
views_NNS were_VBD represented_VBN in_IN the_DT process_NN ._.
To_TO achieve_VB this_DT ,_, we_PRP aim_VBP to_TO work_VB with_IN We_PRP have_VBP hosted_VBN a_DT number_NN of_IN site_NN supranational_JJ organizations_NNS such_JJ as_IN HEALTH_NNP AND_CC SAFETY_NNP visits_NNS by_IN university_NN students_NNS wanting_VBG the_DT World_NNP Health_NNP Organization_NNP WHO_WP We_PRP have_VBP an_DT excellent_JJ safety_NN record_NN to_TO discover_VB more_JJR about_IN biotechnology_NN and_CC the_DT Bill_NNP &_CC Melinda_NNP Gates_NNP Foundation_NNP ,_, and_CC ,_, to_TO date_NN ,_, have_VBP never_RB been_VBN required_VBN and_CC learn_VBP from_IN Acambis_NNP experiences_NNS ._.
both_DT of_IN which_WDT facilitate_VBP the_DT process_NN to_TO report_VB an_DT accident_NN to_TO the_DT Health_NNP For_IN the_DT last_JJ two_CD years_NNS ,_, we_PRP have_VBP also_RB of_IN making_VBG vaccines_NNS available_JJ in_IN and_CC Safety_NNP Executive_NNP in_IN the_DT UK_NNP or_CC sponsored_VBN the_DT Biobusiness_NNPS :_: an_DT insight_NN endemic_JJ regions_NNS ._.
the_DT Operational_NNP Health_NNP and_CC Safety_NNP into_IN bioscience_NN event_NN organised_VBN by_IN the_DT Administration_NN in_IN the_DT US_NNP ._.
As_IN many_JJ Careers_NNP Research_NNP Advisory_NNP Council_NNP ._.
of_IN our_PRP$ employees_NNS regularly_RB work_VBP in_IN a_DT laboratory_NN or_CC manufacturing_NN setting_NN ,_, we_PRP aim_VBP to_TO ensure_VB that_IN effective_JJ health_NN and_CC safety_NN management_NN is_VBZ an_DT integral_JJ part_NN of_IN our_PRP$ business_NN activities_NNS ._.
OUR_NNP EMPLOYEES_NNP 2003_CD RESEARCH_NNP AND_CC DEVELOPMENT_NNP MANUFACTURING_NNP ADMINISTRATION_NNP SALES_NNS AND_CC MARKETING_NN EMPLOYEE_NN NUMBERS_VBZ AT_NNP YEAR_NNP ENDINGS_NNP 2001-2003_CD MARKETED_NNP 2001 2002 2003_CD 0_CD 50 100 150 200_CD 250 300 350_CD
